Lipella Pharmaceuticals Inc. (LIPO)

NASDAQ: LIPO · IEX Real-Time Price · USD
0.685
-0.035 (-4.86%)
At close: Mar 28, 2024, 4:00 PM
0.672
-0.013 (-1.90%)
After-hours: Mar 28, 2024, 6:18 PM EDT

Company Description

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications.

It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus.

Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals logo
Country United States
Founded 2005
IPO Date Dec 20, 2022
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Dr. Jonathan Kaufman M.B.A., Ph.D.

Contact Details

Address:
400 N Lexington St, Ste Ll103
Pittsburgh, Pennsylvania 15208
United States
Phone 412-901-0315
Website lipella.com

Stock Details

Ticker Symbol LIPO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.75
CIK Code 0001347242
ISIN Number US53630L1008
SIC Code 2834

Key Executives

Name Position
Dr. Jonathan Kaufman M.B.A., Ph.D. Co-Founder, Chairman, Chief Executive Officer, President, Secretary and Treasurer
Dr. Michael B. Chancellor M.D. Co-Founder, Chief Medical Officer and Director
Douglas Johnston CPA Chief Financial Officer
Michele Gruber Director of Operations
Katie Johnston Controller

Latest SEC Filings

Date Type Title
Mar 19, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 15, 2024 8-K Current Report
Mar 15, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 15, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 15, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 6, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 6, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 27, 2024 424B3 Prospectus
Feb 27, 2024 10-K Annual Report
Feb 8, 2024 EFFECT Notice of Effectiveness